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Abstract
Purpose
Human papillomavirus (HPV) is the most common sexually transmitted infection globally
and is responsible for a variety of cancers in men and women. An effective HPV vaccine
licensed for use in girls and boys has been indicated for—but is not widely implemented in—
men who have sex with men (MSM). Limited data are available for transgender women
(TW). We explored the social and behavioral aspects related to HPV vaccine uptake and
participation in HPV vaccine studies among Peruvian MSM and TW.
Methods
Focus groups and individual in-depth interviews were conducted to obtain the knowledge,
thoughts, and opinions from Peruvian MSM and TW regarding HPV vaccination. Data were
analyzed using systematic comparative and descriptive content analysis.
Results
Three focus groups and fifteen individual in-depth interviews were conducted among 36
MSM and TW. Participant mean age was 26 years (range 18–40). Though many partici-
pants were unfamiliar with HPV vaccination, most expressed positive attitudes. Participants
expressed concerns about the potential for stigma when disclosing HPV vaccination.
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Conclusion
Peruvian MSM and TW felt that HPV vaccination would be acceptable to themselves and
their peers. Nonetheless, vaccine intake may be impeded by potential stigma. Findings from
this study may guide HPV vaccine implementation in similar populations.
Introduction
Human papillomavirus (HPV) is one of the most common sexually transmitted infections
(STIs). Worldwide, an estimated 630 million people are currently infected with another
500,000 new infections annually [1]. In addition to causing genital warts (GW), HPV is also a
cause of cervical, penile, anal, and some head and neck cancers [2]. Whereas HPV prevalence
in heterosexually identified men is estimated at50% [3], prevalence in men who have sex
with men (MSM) is estimated at 61% (HIV negative) and 93% (HIV positive) [4]. Likewise,
MSM are disproportionally affected by HPV-related sequela than non-MSM, including higher
rates of anogenital and oropharyngeal cancers [5]. Limited data are available for HPV rates
among transgender women (TW), but studies are emerging. One study in Peru reported a
prevalence of any anogenital HPV infection among 68 TW at 95.6%, noting that half of these
women were infected with high risk (i.e. oncogenic) HPV types [6]; a study among 35 TW in
Italy reported HPV DNA in 40% of the subjects, with high risk HPV types detected in 93% of
TW co-infected with HIV [7].
Available HPV vaccines provide significant protection against types 6 and 11, responsible
for 90% of GW, and types 16, 18, 31, 33, 45, 52, and 58, responsible for 70–90% of anogenital
cancers [8]. U.S. immunization policies specifically recommend HPV vaccination for MSM up
to 26 years of age and, as of December 2016, recommend vaccination for transgender persons
to be the same as for all adolescents but extending to age 26 in case of previous inadequate vac-
cination [9]. This policy is congruent with evidence from a modeling study finding HPV vacci-
nation among MSM in the U.S. likely to be cost effective for GW and anal cancer prevention
[10]. Despite the benefits of HPV vaccination, however, uptake among MSM is significantly
lower than the general population [11], and uptake among TW is unknown. In a 2011 online
household sample of 1457 U.S. MSM aged 18–26 years, just 6.8% had received one HPV vac-
cine dose; vaccine uptake was associated with recent STI testing, disclosure of being gay or
bisexual to a doctor, and higher levels of HPV knowledge [12]. In a 2014 systematic review of
16 studies including 5185 MSM (mainly from North America) on HPV and vaccine-related
perceptions, MSM: 1) poorly understood the role of HPV on anogenital and oral cancers; 2)
saw themselves at risk for HPV; and 3) had increased willingness to receive vaccination related
to HPV awareness [13].
In Peru, routine and free HPV vaccine is administered only to adolescent girls in school set-
tings [14] despite an increasingly-documented high burden of HPV in MSM and TW [6, 15,
16]. Peruvian MSM and TW are often aware of HPV by the presence of GW (which is fre-
quently a source of treatment-related shame, stigma, and discrimination) rather than by can-
cer manifestations [17]. With the Peruvian HIV epidemic concentrated among MSM and TW
(estimated at 12.4% and 20.8%, respectively, compared with 0.40% in the general population
[18]), these populations could particularly benefit from HPV vaccination because of the syner-
gistic relationship between HIV and HPV infection [19]. The purpose of this exploratory pilot
study was to characterize the knowledge and beliefs of Peruvian MSM and TW regarding HPV
vaccination in order to better inform its potential introduction into these populations.
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Methods
Participants
Between January and September 2011, we recruited both MSM and TW to participate in either
a focus group or an individual, in-depth interview. Convenience-based recruitment was con-
ducted by peer outreach workers at Epicentro Salud, a community health center serving MSM
and TW in Lima, Peru, and at bars, clubs, volleyball courts, saunas, and parks frequented by
these populations. Peer outreach workers visited the various venues, approached potential par-
ticipants, and explained the purpose of the study as a research project to understand the views,
opinions and knowledge of MSM and TW on HPV treatment and prevention. To ensure
sample diversity, we recruited MSM who self-identified as ‘‘gay” as well as those not self-iden-
tifying as gay, and MSM and TW who reported paid sex work as well as those who did not.
Interested individuals were referred to the study site where they were screened for eligibility
(18 years of age, reported sex with a male in the previous 12 months) and assigned to partici-
pate in either a focus group or an individual, in-depth interview.
Procedures
The focus groups and the individual, in-depth interviews took place in a private room; each
lasted approximately 60 minutes. Two Peruvian psychologists experienced in qualitative meth-
ods and HIV/STI prevention with MSM and TW conducted the sessions that were audio
recorded on digital media. At the beginning of focus groups and interviews, participants
received a verbal explanation of HPV including information regarding: transmission; preva-
lence; types; GW; common HPV-related cancers (cervical and anal); Peruvian MSM and TW
as special populations disproportionately affected by HPV; and HPV and other STIs including
HIV. Photographs of anogenital GW were shown to assure comprehension, and participants
were encouraged to ask questions at any time during the introduction or during the focus
groups or interviews.
Focus groups and in-depth interviews used a semi-structured guide with questions and
probes on HPV vaccination including: vaccine knowledge, acceptability, social and commu-
nity concerns (including the impact of vaccines on an individual’s social life and sexual prac-
tices), and participation in HPV vaccine research. Table 1 shows the main question domains,
types, and probes used for both the focus groups and interviews.
All participants provided informed consent prior to study participation and received 15
Nuevos Soles (approximately US $5.60 in 2011) for transportation. Ethics approval was
obtained from the Universidad Peruana Cayetano Heredia.
Data analysis
Audio recordings were transcribed verbatim. A Peruvian anthropologist experienced in STI
research (CRN) performed a systematic, comparative, and descriptive content analysis by cod-
ing and grouping the information thematically, extracting similarly coded data into matrices,
and identifying recurring issues and differences in the narratives. A second, bilingual reviewer
(JTG) confirmed the analysis and discrepancies were mutually resolved. Representative quotes
for each theme were translated into English for results reporting. Data are sorted as either
from an individual interviewee or focus group and from MSM or TW.
Results
Three focus groups (two with MSM and one with TW) and fifteen individual, in-depth inter-
views (10 MSM, 5 TW) were conducted for a total sample size of 36 MSM and TW participants.
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The mean participant age was 26 (range 18–40). The main emergent themes included: the pur-
pose of vaccines in general and the HPV vaccine in particular; acceptability and motivation for
HPV vaccination; HPV vaccination and sexual behavior; social aspects and HPV vaccination;
and attitudes towards HPV vaccination research. Table 2 includes additional quotes supple-
menting the illustrative quotes presented in this section; see S1 Data for the unabridged qualita-
tive data analysis. For the in-depth interviews, the number identifier refers to an individual
participant.
Purpose of vaccines and the HPV vaccine
Most participants grasped the preventive aspect of vaccines in general, though there was con-
fusion among some whether vaccines cure, treat, or control disease:
“[A vaccine is] to control or heal a certain disease.”
(Focus Group, MSM)
"I think if I get vaccinated against the infection, I am going to ‘nip the infection in the bud,’ . . .
like a treatment. It won’t be overnight, and it will be slow, but it will be a treatment."
(Interviewee-3, MSM)
Acceptability and motivation for HPV vaccination
Some participants had previously heard about the HPV vaccine and the majority expressed
interest in receiving it. Reasons mentioned for accepting the vaccine were the prevention of
GW, avoiding infecting others with HPV, as a way to get more information about HPV and
GW, and providing a sense of security and serving as a role model for others:
Table 1. Guide for focus groups and in-depth interviews among Peruvian men who have sex with men and transgender women regarding HPV
and HPV vaccine acceptability.
Domain Question Probes
HPV Vaccine Do you know if there is a vaccine that prevents HPV infection? What have you heard?
Facilitators and Barriers to
HPV vaccination
If there were an HPV vaccine available to you in Peru, would you
vaccinate yourself?
Why or why not?
Do you think your friends would get vaccinated? Why or why not?
Do you think your life would change if you were to get vaccinated? How so?
Behavioral Issues Do you think people would change their sexual behaviors if they
were to get vaccinated?
How would they change? To what extent could
behaviors change?
Do you think that condom use by MSM and TW could change after
getting vaccinated for HPV?
What about protection against other sexually
transmitted infections besides HPV?
Cultural and Social Issues Do you think that men who have sex with men and transgender
women in Peru are ready to get the HPV vaccine?
Why or why not?
Do you think your family or friends would question you or bother you
if you were to decide to get vaccinated?
Why or why not?
If you decided to get vaccinated would you tell your friends or
family?
What differences might there be between different
groups?
HPV Vaccine Research What do you think about the possibility of an HPV vaccine study
being conducted in Peru for MSM and TW?
Would you participate? Why or why not?
What might convince you to participate?
doi:10.1371/journal.pone.0172964.t001
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Table 2. HPV vaccine knowledge and acceptability among Peruvian men who have sex with men and
transgender women: Additional quotes supporting each of the identified themes.
Theme Representative Quotes*
Purpose of vaccines and the HPV
vaccine
• “There is an. . .injection that helps control the virus, right?”
(Interviewee-10, TW)
• "I would [like to] receive the vaccine to cure me or to keep me
from being infected with warts." (Interviewee-13, MSM)
• “[A vaccine] controls the [body’s] defenses, doesn’t it?” (Focus
Group, MSM)
• “[A vaccine] provides defense against what is going to infect us;
we have defenses for that to control it.” (Focus Group, MSM)
Acceptability and motivation for
HPV vaccination
• “I would be a role model example [for others]. Better yet, I would
say, ‘I already received the HPV vaccine,’ and it would benefit
me because I would be safe against infection. . .” (Interviewee-
11, MSM)
• “I would receive the vaccine because I am going to . . . prevent
[warts], right? In other words. . . I’m going to be protected with
[the vaccine], right? However much intercourse I have, I think I
will be cured against HPV.” (Interviewee-6, TW)
• “I have a girlfriend and she doesn’t know everything about me. I
do not want to infect her.” (Interviewee-3, MSM)
• “There is not much information about HPV.” (Focus Group,
MSM)
• “MSM are not prepared to receive the vaccine because they are
not aware of the issue, and some will not do it of their own
accord. In other words, they either don’t know about it or they
ignore it.” (Interviewee-5, MSM)
HPV vaccination and sexual
behavior
• “You get the HIV test, you take care, but it does not end there
because there are other [sexually transmitted infections].”
(Focus Group, MSM)
• “Yes [I would continue using condoms], because the condom
protects you from all diseases, while the vaccine only protects for
HPV.” (Interviewee-9, MSM)
• “If I received the vaccine, I would be protecting my sexual
partner, right? Sexually speaking?” (Interviewee-2, MSM)
Social aspects and HPV
vaccination
• “I am an independent person and I make my own decisions. If I
mention it to them [my family], they might be uncomfortable, but
it is up to me to tell them or not.” (Interviewee-2, MSM)
• “No [I would not tell my friends]; it’s personal and they don’t have
to know. This decision is mine, and they will mock me if I am
vaccinated because they see it as a weakness. They will think I
like faggots, and then the entire neighborhood will know. They
would make fun of me, and I know my brothers and friends would
participate [in ridiculing me].” (Interviewee-13, MSM)
Attitudes towards HPV vaccine
research participation
• "I would get vaccinated as long as there are no abnormal
reactions, and I didn’t have any problems [getting the vaccine]."
(Interviewee-10, TW)
• “[The studies] sound good. Many things can be avoided, I don’t
know, to avoid warts, right? Sex workers are more exposed to
that.” (Interviewee-7, MSM)
• “I think [whether one participates] depends on many things,
including shame and fear.” (Focus group, MSM)
• “Like I told you before, I will come running to new projects. I am
always looking for the treatments." (Interviewee-8, TW)
*Numbers for Interviewees are used to distinguish between different participants.
MSM: men who have sex with men; TW: transgender woman
doi:10.1371/journal.pone.0172964.t002
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"I would like to protect myself, to not infect others."
(Interviewee-2, MSM)
"My friends, transgender people, would accept vaccination because no one wants warts in the
anus."
(Interviewee-7, TW)
Vaccine cost was also mentioned as a factor related to vaccine uptake:
"The truth is that I didn’t know about HPV vaccines. But if they are implemented, and they
are free, yes, I would get it now."
(Interviewee-4, MSM)
The potential for vaccine acceptance by peers was expressed in different ways. Some
thought such vaccines would be well-received by others due to its protective benefits while oth-
ers believed their friends downplayed the risk of STI, or they would prefer to maintain private
matters relating to sex with MSM or TW.
"Interviewer: Do you think that your friends here in the neighborhood, both the ones you hang
out with and the ones that tend to have sex with men, would get vaccinated?
Participant: I don’t know; it is the individual’s choice! Here, they are all on the down-low,
always denying they have sex with men."
(Interviewee-14, MSM)
HPV vaccination and sexual behavior
Several participants thought receiving the vaccine would encourage or increase condom use
and STI information seeking:
“In my case, I would continue using condoms because I would not be protected from other dis-
eases or AIDS, right?"
(Interviewee-13, MSM)
“[Being vaccinated] serves as a warning and makes me more conscious of my behavior."
(Interviewee-12, MSM)
When asked if sexual conduct would change once vaccinated for HPV, however, some par-
ticipants predicted increased sexual risk-taking due to a bolstered sense of safety:
“They will feel more secure [once vaccinated for HPV], right? Or maybe they will be more irre-
sponsible because they will say, ‘I’ve been vaccinated, and I am not at risk of being infected
with that [HPV].’”
(Interviewee-2, MSM)
Social aspects and HPV vaccination
Many participants said they would tell their families and friends if they were vaccinated. One
reason for this disclosure was perception of vaccination as a “health issue” carrying both dis-
ease prevention benefits and potential risk:
HPV vaccine acceptability in Peruvian MSM and TW
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“. . .if I tell [my family] that I am going to be vaccinated to prevent disease, I think that they
would support me."
(Interviewee-6, TW)
“My family should know because vaccines are unpredictable and there are so many side effects;
I would want them to be aware if something happens to me."
(Interview-14, MSM)
However, predictions of vaccine disclosure acceptance was not universal, especially among
participants’ friends:
“My friends would say, ‘Why are you doing so much to control the disease?We all die from
something.’”
(Interviewee-10, TW)
Stigma was predicted to be a potential outcome when disclosing one’s HPV vaccination to
others, but may be managed in different ways depending on the audience. For example, one
interviewee said that he could tell his family about his HPV vaccination, and though their reac-
tion could be to confuse vaccination with HPV infection, he could nonetheless correct their
misunderstanding. With friends, however, his strategy would be to refrain from disclosing
HPV vaccination so as to avoid potential ridicule:
“[My family] would think I had the disease, or that I was affected by it. I would tell them that
the vaccine is prevention, though. I think, for my sake, they would not say anything. I wouldn’t
say anything to my friends until my results came out. They might take it the wrong way, make
fun of me, or think I am infected."
(Interviewee-5, MSM)
Attitudes towards HPV vaccine research participation
Study participants mainly endorsed HPV vaccine research, citing positive health benefits and
taking advantage of research in Peru as incentives:
“They are doing good for the health of the people. As a MSM person, I would receive [the vac-
cine]; everyone should be concerned about their health.”
(Interviewee-4, MSM)
“[Peru] seems perfect to me [for an HPV vaccine study], right? Thank God they provide this
opportunity here and not somewhere else. We are a part of the science."
(Interviewee-9, TW)
Among the reasons cited for not wanting to participate in HPV vaccine research were
potential side effects, or “abnormal reactions” and one TW specifically noted the vaccine injec-
tion site as a concern since gender conforming implants could interfere:
“Some medical providers have learned to ask if transgender women have silicone in their back-
sides because they cannot use the penicillin shot there and must use the arm instead.”
(Focus Group, TW)
HPV vaccine acceptability in Peruvian MSM and TW
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As for vaccine disclosure, concerns were raised about what others may say about their par-
ticipation in a HPV-related study, in this case going to a research site that was known for work
with MSM:
“People don’t want to [come to the study site for research] because they are not in the scene.
They say: ‘It is just queers, it is just for queers.’”
(Focus group, MSM)
Discussion
This is the first study in Peru, and one of very few globally, specifically investigating the accept-
ability of HPV vaccination in MSM and TW. The chief finding is that the acceptability of a pre-
ventive HPV vaccine was widespread but not universal among these populations depending
on a range of factors. While HPV vaccination was sometimes incorrectly perceived as curative
or therapeutic, rather than preventive, reasons for wanting HPV vaccination centered on not
only self-protection but the protection of sexual partners (including female partners), preven-
tion of GW, and to serve as a role model for others.
Chief among the barriers to HPV vaccination, as well as participation in HPV vaccination
research, was the potential for physical and social vaccine-induced harm. Physical harm is a
concern easily addressed given the vaccines’ excellent safety record and expectation that it will
“do no harm” (i.e., be free from side effects). TW’s concerns about the vaccine administration
interfering with silicone implants located in the buttocks can be managed by explaining that
the vaccine site is the muscle in the upper arm.
Concerns regarding possible social harms, however, will be harder to assuage. MSM in par-
ticular worried about the stigma associated with their sexual behaviours, an understandable
concern in Peru where 8 assassinations due to homophobia occurred in the past year alone
[20]. Similar concerns have been documented in these populations in Peru regarding the
acceptability of preexposure prophylaxis (PrEP) for HIV infection [21] and rectal microbicides
[22]. Unfortunately, though participants’ concerns regarding stigma were related to their
friends and family, the health delivery system presents additional challenges. Access to HPV
vaccination (as with other sexual health services) relies on an accurate sexual history which is
often hindered by MSM and TW’s fear of discrimination [23, 24]. This issue is compounded
by the fact that perceived susceptibility to HPV-related cancers and genital warts is often low
among MSM to begin with [25] (cancer prevention was not mentioned in neither the focus
groups nor the in-depth interviews as a motivating factor for HPV vaccination) thus patients
may not even think to ask their medical provider about these issues. Though to do so would
require an increased investment, the only sure path to reaching all MSM and TW would be to
implement universal vaccination for all adolescents, girls and boys. Besides increased costs,
opponents of this approach cite “herd immunity” which develops after 50% of the female pop-
ulation is vaccinated thereby conferring protection to their unvaccinated partners [26]. Unfor-
tunately, however, not only is the HPV vaccination rate of girls in Peru well below 50% [27],
but for MSM and TW, herd immunity based on the vaccination of females would likely pro-
vide little or no protection. Universal vaccination could avoid sex and gender inequalities,
boost overall vaccination and protection rates regardless of sex, gender and sexual orientation,
and preempt potentially stigmatizing situations faced by adult MSM and TW requesting the
vaccine.
Risk compensation (or sexual disinhibition) surfaced as a possibility by one participant who
felt that peers could be sexually “irresponsible” following HPV vaccination, though this was a
HPV vaccine acceptability in Peruvian MSM and TW
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minority view. Risk compensation among vaccine-aged adolescent girls and boys is still hotly
debated (particularly among parents) despite a lack of evidence that either riskier sexual behav-
iors or STI rates increase post HPV vaccination [28]. Given that a similar discourse continues
in the HIV biomedical prevention field among MSM and TW [29], research is necessary to
further understand the potential for sexual behavior changes among MSM and TW after
receiving HPV vaccination.
Another factor which was mentioned in our study as affecting HPV vaccine uptake and
requires deeper investigation is the effect of vaccine price on vaccine uptake. In the Peruvian
HPV vaccination program, given that the program has not been extended to boys, inclusion of
MSM and TW in the immediate future seems improbable. Not surprisingly, price had a pro-
found effect on HPV vaccine acceptability in a sample of Hong Kong MSM, with 80% of par-
ticipants finding a vaccine acceptable when it was free, compared to 30% when it was offered
at the current market price [30]. In Peru, product price has also been demonstrated to influ-
ence the potential uptake of novel HIV prevention interventions, with a clear preference for
low- or no cost alternatives (even in scenarios where other product characteristics such efficacy
and side effects lessened) [21, 31, 32]. Unfortunately, these data do not bode well for wide-
spread, out-of-pocket HPV vaccination, especially in lower and middle income countries like
Peru, where 3 doses of Cervarix1 and Gardasil1 currently cost $195 and $270 respectively, or
approximately 57%-78% of an the average Peruvian monthly salary [33]. Thus, HPV vaccina-
tion for MSM and TW will be out of reach except for the few who can pay for it unless either
all adolescent boys (regardless of sexual and gender orientation) are included in the National
Vaccine Plan or, in lieu of routine vaccination for boys, MSM and TW are strategically tar-
geted for vaccination. Studies exploring the economic benefits of HPV vaccination for MSM
and TW (e.g., number of genital wart cases requiring treatment averted; number of prevent-
able HPV-associated cancers averted, etc.) should also be conducted to inform policy changes.
Limitations to our study are related to its small, formative nature that precluded several
methodological enhancements necessary in future studies. More in-depth demographic and
sexual behavior information from participants should be included in future studies in order to
triangulate and further contextualize the findings and thereby strengthen its generalizability.
Also, while we strived to recruit a study sample reflective of Peruvian MSM and TW which
included MSM who did not identify as gay and both MSM and TW reporting paid sex work,
the small overall sample size and thus sub-group sizes led to focus groups of all MSM or all
TW, thereby preventing the ability to attribute specific quotes to MSM types. Finally, not all
participants were < 26 years of age (the US CDC recommended cut-off age for HPV vaccina-
tion in MSM [9]); however, not only was this study conducted before this age recommenda-
tion was published, but this does not invalidate participant opinions for a vaccine they may
have been eligible to receive. These limitations notwithstanding, this small study still repre-
sents the first step in exploring HPV vaccine acceptability among MSM and TW in Peru and
to our knowledge in South America. Future studies should also consider expanding beyond
the target vaccine populations to include the views and opinions of those who would act as the
likely gateway not only to HPV vaccination but for education and treatment of HPV and its
sequelae, as well: nurses, doctors and health professionals [17].
As Nadarzynski et al. [13] point out in their systematic review of literature examining HPV
vaccine-related perceptions among MSM, in environments where HPV vaccination is sex-spe-
cific (as in Peru), theory-driven studies focusing on the specific demographic, behavioral and
psychosocial factors related to vaccine uptake are essential. Particularly in young and/or sexu-
ally inexperienced MSM and TW, understanding with precision the factors predicting HPV
vaccination uptake would lay the foundation for vaccine introduction into these populations,
by either public or community-based entities.
HPV vaccine acceptability in Peruvian MSM and TW
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Conclusion
MSM and TW in Peru and elsewhere are disproportionally infected and affected with HPV
and related sequelae, and co-infection with HIV greatly increases the rates of anogenital and
oral cancers in these populations. Unlike HIV, however, safe and effective HPV vaccines have
been available for years now with varied vaccine uptake success dependent on the setting.
Therefore, in addition to future research on the individual factors affecting (or which could
potentially affect) HPV vaccine uptake, implementation science should also be applied at the
policy and healthcare delivery systems levels so that populations in particularly high need can
receive the vaccine in a systematic and sustainable way.
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